Everence Capital Management Inc. Makes New $272,000 Investment in Astrana Health, Inc. (NASDAQ:ASTH)

Everence Capital Management Inc. acquired a new position in Astrana Health, Inc. (NASDAQ:ASTH) in the 3rd quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The firm acquired 4,690 shares of the company’s stock, valued at approximately $272,000.

Other institutional investors and hedge funds have also bought and sold shares of the company. SG Americas Securities LLC purchased a new stake in Astrana Health in the 3rd quarter worth approximately $680,000. Granite Bay Wealth Management LLC bought a new position in shares of Astrana Health in the 3rd quarter worth approximately $290,000. GAMMA Investing LLC bought a new position in shares of Astrana Health in the 3rd quarter worth approximately $34,000. Handelsbanken Fonder AB bought a new position in shares of Astrana Health in the 3rd quarter worth approximately $492,000. Finally, Central Pacific Bank Trust Division bought a new position in shares of Astrana Health in the 3rd quarter worth approximately $160,000. Hedge funds and other institutional investors own 52.77% of the company’s stock.

Astrana Health Stock Performance

Shares of ASTH opened at $57.90 on Wednesday. The business’s fifty day simple moving average is $53.62 and its two-hundred day simple moving average is $46.13. The company has a current ratio of 1.84, a quick ratio of 1.84 and a debt-to-equity ratio of 0.62. Astrana Health, Inc. has a 12 month low of $28.86 and a 12 month high of $63.20. The company has a market cap of $3.24 billion, a price-to-earnings ratio of 43.86, a P/E/G ratio of 2.20 and a beta of 1.21.

Astrana Health (NASDAQ:ASTH) last issued its earnings results on Wednesday, August 7th. The company reported $0.40 EPS for the quarter, beating the consensus estimate of $0.39 by $0.01. Astrana Health had a return on equity of 10.71% and a net margin of 4.30%. The business had revenue of $486.30 million for the quarter, compared to the consensus estimate of $440.68 million. During the same period last year, the business posted $0.28 EPS. The company’s revenue was up 39.7% compared to the same quarter last year. Research analysts anticipate that Astrana Health, Inc. will post 1.33 earnings per share for the current fiscal year.

Analyst Ratings Changes

Several research analysts have recently issued reports on ASTH shares. Stifel Nicolaus increased their target price on Astrana Health from $48.00 to $60.00 and gave the stock a “buy” rating in a research report on Thursday, August 1st. Truist Financial increased their target price on Astrana Health from $50.00 to $59.00 and gave the stock a “buy” rating in a research report on Friday, August 9th. KeyCorp began coverage on Astrana Health in a research report on Friday, October 11th. They issued a “sector weight” rating for the company. Robert W. Baird raised their price objective on Astrana Health from $54.00 to $67.00 and gave the company an “outperform” rating in a research report on Thursday, August 15th. Finally, BTIG Research raised their price objective on Astrana Health from $60.00 to $70.00 and gave the company a “buy” rating in a research report on Thursday, October 3rd. One equities research analyst has rated the stock with a hold rating, six have issued a buy rating and one has assigned a strong buy rating to the company’s stock. Based on data from MarketBeat.com, Astrana Health presently has a consensus rating of “Buy” and an average target price of $62.00.

Astrana Health Profile

Astrana Health, Inc, Inc, a physician-centric technology-powered healthcare management company, provides medical care services in the United States. It operates through three segments: Care Partners, Care Delivery, and Care Enablement. The company is leveraging its proprietary population health management and healthcare delivery platform, operates an integrated, value-based healthcare model which empowers the providers in its network to deliver care to its patients.